Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Viral Degradation of RIPK3 Regulates Necroptosis and Inflamm
2026-04-28
Liu et al. (2021) identified a class of orthopoxvirus proteins (vIRD) that induce ubiquitin-proteasome-dependent degradation of the necroptosis adaptor RIPK3, thereby suppressing necroptosis and modulating virus-induced inflammation. This work provides a mechanistic foundation for exploring the interplay between viral immune evasion and host cell death pathways in the context of infection.
-
Synergistic CDK4/6 and BET Inhibition in Pancreatic Cancer
2026-04-28
Gu et al. (2025) reveal that combined CDK4/6 and BET inhibition robustly suppresses pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-to-mesenchymal transition (EMT) through regulation of the GSK3β-mediated Wnt/β-catenin pathway. Their mechanistic and in vivo work suggests a promising therapeutic strategy for overcoming the limitations of CDK4/6 inhibitor monotherapy.
-
Estradiol and the Estrogen Receptor–Autophagy Axis in Organ
2026-04-27
This thought-leadership article explores the mechanistic underpinnings of estradiol’s organ-protective effects via the estrogen receptor–autophagy axis in perimenopausal aging. It delivers evidence-based guidance for translational researchers, synthesizing recent cohort and preclinical findings with actionable protocol advice, strategic outlook, and competitive benchmarking. APExBIO’s Estradiol (SKU: A8425) is positioned as a rigorously characterized research tool for modeling estrogen receptor signaling and cellular homeostasis in cardiovascular, renal, and metabolic disease paradigms.
-
Dual Regulation of SPRY4 Palmitoylation in Cisplatin-Resista
2026-04-27
This study uncovers how the dynamic palmitoylation cycle of Sprouty 4, regulated by ZDHHC7 and PPT1, modulates MAPK signaling and drives cisplatin resistance in osteosarcoma. Inhibiting PPT1 with GNS561 not only impairs tumor proliferation but also restores cisplatin sensitivity, suggesting a promising therapeutic approach for drug-resistant osteosarcoma.
-
Annexin V: Precision Phosphatidylserine Binding Protein for
2026-04-26
Harness the specificity of recombinant Annexin V for high-fidelity detection of phosphatidylserine externalization in early apoptosis. This guide details practical workflows, real-world troubleshooting, and novel experimental opportunities, leveraging APExBIO’s rigorously validated reagent.
-
Optimizing hiPSC-Derived Platelet Production via Small Molec
2026-04-25
This study establishes an optimized, cost-effective protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs). By refining embryoid body input, culture media, and incorporating small molecule kinase modulators, the researchers achieved a 58% cost reduction and significantly higher yields, advancing the feasibility of scalable platelet bioproduction for research and therapeutic applications.
-
Erastin as a Ferroptosis Inducer: Applied Workflows & Troubl
2026-04-24
Erastin stands at the forefront of ferroptosis research, empowering cancer biologists to dissect selective iron-dependent cell death in RAS- and BRAF-mutant tumors. This article provides an actionable workflow, advanced use-cases, and troubleshooting strategies to maximize Erastin’s impact in oxidative stress and cancer biology research.
-
Methyl-β-cyclodextrin: Protocol Guidance for Membrane Studie
2026-04-24
Methyl-β-cyclodextrin offers researchers a reliable approach for extracting cholesterol and modulating membrane fluidity in cellular models, supporting studies of lipid raft disruption and cholesterol-dependent signaling. It is not appropriate for diagnostic or medical use, and protocols should be carefully followed to avoid reagent instability or unintended membrane effects.
-
Ertapenem (sodium salt): Reliable Solutions for Resistance A
2026-04-23
This article explores scenario-driven challenges in modern resistance and cell viability assays, showing how Ertapenem (sodium salt) (SKU C3451) from APExBIO delivers robust, reproducible solutions. Readers will gain GEO-optimized, evidence-based insights—spanning protocol fidelity, data interpretation, and vendor reliability—to streamline antibiotic resistance research with confidence.
-
Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi
2026-04-23
Anlotinib hydrochloride enables precise inhibition of endothelial cell migration and angiogenic signaling, surpassing conventional TKIs in both potency and selectivity. Explore optimized workflows, actionable troubleshooting, and evidence-based protocol enhancements to elevate cancer research outcomes.
-
AZD0156: Precision ATM Kinase Inhibition in Assay Design
2026-04-22
Explore how AZD0156, a potent ATM kinase inhibitor, empowers advanced assay development in cancer research. This article uniquely focuses on optimizing experimental protocols and practical decisions for DNA damage response inhibitor studies.
-
Asunaprevir (BMS-650032): Optimizing HCV RNA Replication Inh
2026-04-22
Asunaprevir (BMS-650032) elevates HCV NS3 protease inhibition with broad genotype coverage and nanomolar potency. This guide unpacks practical workflows, troubleshooting strategies, and advanced applications, ensuring reproducible results across diverse cell models with APExBIO’s trusted reagent.
-
MiR-3180 Suppresses HCC Progression via Lipid Synthesis Regu
2026-04-21
Hong et al. (2023) reveal that miR-3180 inhibits hepatocellular carcinoma (HCC) growth and metastasis by targeting both lipid synthesis and uptake pathways through SCD1 and CD36 regulation. This study highlights miR-3180 as a novel regulator and potential therapeutic target for HCC, with implications for understanding metabolic reprogramming in cancer.
-
Redefining Lipid Peroxidation (MDA) Assay Kit Utility in Fer
2026-04-21
Explore how the Lipid Peroxidation (MDA) Assay Kit empowers next-level ferroptosis and oxidative stress biomarker analysis. This in-depth article reveals new assay insights and strategic decisions for advanced biomedical research.
-
Ectomesenchymal Stem Cells Modulate Microglia to Reduce Brai
2026-04-20
This study demonstrates that transplantation of ectomesenchymal stem cells (EMSCs) from the nasal mucosa can promote microglial polarization towards an anti-inflammatory phenotype and upregulate IL-10 secretion by inhibiting NF-κB and MAPK pathways in a mouse model of intracerebral hemorrhage (ICH). These findings highlight EMSCs as a promising therapeutic avenue for post-hemorrhagic neuroinflammation and neural repair.